In mass media and popular culture, medical research is often framed as a race to overcome a complex, seemingly insurmountable challenge, with lives hanging in the balance.
Jul 26, 2016
0
5
Hepatitis is inflammation in the liver caused by specific viruses. The hepatitis viruses are referred to as types A, B, C, D and E. All types affect the liver, but they differ in illness severity and prevention options.
Jan 25, 2024
0
3
A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.
Dec 15, 2020
0
9
Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is deadly pneumonia that has killed more ...
Sep 8, 2013
0
0
With a new method for examining virus samples researchers from the University of Copenhagen have solved an old riddle about how Hepatitis C virus avoids the human body's immune defenses. The result may have an impact on how ...
Jul 5, 2023
0
22
A combination of two cancer drugs inhibited both dengue and Ebola virus infections in mice in a study led by Stanford University School of Medicine researchers, despite the fact that these two viruses are vastly different ...
Feb 27, 2017
0
54
In a multicenter phase 3 trial, researchers at the MHH have demonstrated the efficacy and safety of the drug bulevirtide, which prevents HD viruses from entering the liver. This paves the way for a drug therapy of the particularly ...
Jun 22, 2023
0
12
The importance of access to highly effective direct acting antiviral (DAA) treatments to help eliminate hepatitis C (HCV) among people living with HIV (PLHIV) has been demonstrated in new research led by Burnet Institute, ...
Jan 16, 2023
0
44
Globally, an estimated 71 million people are living with chronic hepatitis C virus (HCV). Over decades of infection, chronic HCV infection results in progressive damage to the liver and an increased risk for end stage liver ...
Jun 8, 2017
0
20
A 300-mg dose of bepirovirsen per week for 24 weeks results in sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in 9–10% of patients with chronic HBV infection, according to a study published ...
Nov 14, 2022
0
27
